Phase 1b study of safety, tolerability and efficacy of R1507, a monoclonal antibody to IGF-1R in combination with multiple standard oncology regimens in patients with advanced solid malignancies

Cancer Chemotherapy and Pharmacology

Volumn 73, Issue 3, 2014, Pages 467-473

  Mahadevan, Daruka ^a   Sutton, Gregory Ryan ^a   Arteta Bulos, Rafael ^a   Bowden, Chris J ^b   Miller, Paul J E ^c   Swart, Rachel Elizabeth ^d   Walker, Mark S ^c   Haluska, Paul ^e   Munster, Pamela N ^f   Marshall, John ^g   Hamid, Omid ^h   Kurzrock, Razelle ⁱ  

^a UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^b GENENTECH INC   (United States)

^c ACORN Research LLC   (United States)

^d Arizona Oncology Associates   (United States)

^e MAYO CLINIC   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

^g GEORGETOWN UNIVERSITY HOSPITAL   (United States)

^h Angeles Clinic and Research Institute   (United States)

ⁱ UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

IGF R1; Monoclonal antibody; Oncology regimens; Phase 1; R1507; Solid Tumor

Indexed keywords

ANTINEOPLASTIC AGENT; BEVACIZUMAB; CAPECITABINE; CARBOPLATIN; ERLOTINIB; ETOPOSIDE; GEMCITABINE; MONOCLONAL ANTIBODY; PACLITAXEL; R 1507; SORAFENIB; TRASTUZUMAB; UNCLASSIFIED DRUG;

ADVERSE OUTCOME; ANEMIA; ARTICLE; ASTHENIA; BONE MARROW SUPPRESSION; BRAIN ISCHEMIA; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; COLON CANCER; DEHYDRATION; DIARRHEA; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HEMOLYSIS; HUMAN; HYPERGLYCEMIA; KIDNEY CANCER; LIVER FAILURE; LOADING DRUG DOSE; LUNG CANCER; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MELANOMA; MUCOSA INFLAMMATION; NASOPHARYNX CANCER; NAUSEA; PANCREAS CANCER; PANCREATITIS; PANCYTOPENIA; PHASE 1 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; SIDE EFFECT; SKIN CANCER; SOFT TISSUE CANCER; SOLID TUMOR; STOMACH CANCER; THROMBOCYTOPENIA;

ADMINISTRATION, INTRAVENOUS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; RECEPTOR, IGF TYPE 1;

EID: 84896040011     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-013-2372-x     Document Type: Article

References (27)

1. Pollak MN, Schernhammer ES, Hankinson SE (2004) Insulin-like growth factors and neoplasia. Nat Rev Cancer 4(7):505-518 (Pubitemid 38868620)
2. Baserga R (2005) The insulin-like growth factor-I receptor as a target for cancer therapy. Expert Opin Ther Targets 9(4):753-768
3. Kurmasheva RT, Houghton PJ (2006) IGF-I mediated survival pathways in normal and malignant cells. Biochim Biophys Acta 1766(1):1-22 (Pubitemid 44175635)
4. Sachdev D, Yee D (2007) Disrupting insulin-like growth factor signaling as a potential cancer therapy. Mol Cancer Ther 6(1):1-12 (Pubitemid 46206663)
5. Tao Y, Pinzi V, Bourhis J, Deutsch E (2007) Mechanisms of disease: signaling of the insulin-like growth factor 1 receptor pathway-therapeutic perspectives in cancer. Nat Clin Pract Oncol 4(10):591-602 (Pubitemid 47534758)
6. Stattin P, Bylund A, Rinaldi S et al (2000) Plasma insulin-like growth factor-I, insulin-like growth factor-binding proteins, and prostate cancer risk: a prospective study. J Natl Cancer Inst 92:1910-1917 (Pubitemid 32036921)
7. Rosen N, Yee D, Lippman ME et al (1991) Insulin-like growth factors in human breast cancer. Breast Cancer Res Treat 18(suppl 1):S55-S62
8. Angelloz-Nicoud P, Binoux M (1995) Autocrine regulation of cell proliferation by the insulin-like growth factor (IGF) and IGF binding protein-3 protease system in a human prostate carcinoma cell line (PC-3). Endocrinology 136:5485-5492
9. Rotsch M, Maasberg M, Erbil C et al (1992) Characterization of insulin-like growth factor 1 receptors and growth effects in human lung cancer cell lines. J Cancer Res Clin Oncol 118:502-508
10. Culouscou JM, Shoyab M (1991) Purification of a colon cancer cell growth inhibitor and its identification as an insulin-like growth factor binding protein. Cancer Res 51:2813-2819
11. Sekyi-Otu A, Bell RS, Ohashi C et al (1995) Insulin-like growth factor 1 (IGF-1) receptors, IGF-1, and IGF-2 are expressed in primary human sarcomas. Cancer Res 55:129-134
12. Bergmann U, Funatomi H, Kornmann M et al (1996) Increased expression of insulin receptor substrate-1 in human pancreatic cancer. Biochem Biophys Res Commun 220:886-890 (Pubitemid 26198607)
13. Goetsch L, Gonzalez A, Leger O et al (2005) A recombinant humanized anti- insulin-like growth factor receptor type I antibody (h7C10) enhances the antitumor activity of vinorelbine and anti-epidermal growth factor receptor therapy against human cancer xenografts. Int J Cancer 113(2):316-328 (Pubitemid 39628325)
14. Lu D, Zhang H, Koo H et al (2005) A fully human recombinant IgG-like bispecific antibody to both the epidermal growth factor receptor and the insulin-like growth factor receptor for enhanced antitumor activity. J Biol Chem 280(20):19665-19672 (Pubitemid 41379490)
15. Morgillo F, Kim WY, Kim ES, Ciardiello F, Hong WK, Lee HY (2007) Implication of the insulin-like growth factor-IR pathway in the resistance of non-small cell lung cancer cells to treatment with gefitinib. Clin Cancer Res 13(9):2795-2803 (Pubitemid 46788049)
16. Morgillo F, Woo JK, Kim ES, Hong WK, Lee HY (2006) Heterodimerization of insulin-like growth factor receptor/epidermal growth factor receptor and induction of survivin expression counteract the antitumor action of erlotinib. Cancer Res 66(20):10100-10111 (Pubitemid 44672064)
17. Karp, D et al (2007) Efficacy of the anti-insulin like growth factor I receptor (IGF- 1R) antibody CP 751871 in combination with paclitaxel and carboplatin as first-line treatment for advanced non-small cell lung cancer (NSCLC). J Clin Oncol, ASCO Annual Meeting Proceedings Part I. Vol 25, No. 18S (June 20 Supplement), 7506
18. Karp, D (2008) High Activity of the anti-IGFR antibody CP-751,871 in combination with paclitaxel and carboplatin in squamous cell carcinoma. J Clin Oncol 26: 2008 ASCO Annual Meeting Proceedings Part I. Vol 25, No. 18S (May 20 suppl; abstr 8015)
19. Sarantopoulos, J et al (2008) A phase 1B study of AMG 479, a type 1 insulin-like growth factor receptor (IGF-1R) antibody, in combination with panitumumab(P) or gemcitabine (G). J Clin Oncol 26: 2008 ASCO Annual Meeting Proceedings Part I. Vol 25, No. 18S (May 20 suppl; abstr 3583)
20. Razelle Kurzrock, Amita Patnaik, Joseph Aisner et al (2010) A Phase I Study of Weekly R1507, a human monoclonal antibody insulin-like growth factor-I receptor antagonist in patients with solid tumors. Clin Cancer Resm 16:2458-2465
21. Von Hoff DD, Nieves JA, Vocila LK, Weitman SD, Cvitkovic EC (2007) The complete phase Ib clinical trial: A method to accelerate new agent development. J Clin Oncol 25(18S 2007 ASCO Annual Meeting Proceedings Part I, abstract 2562)
22. National Cancer Institute (2006) CTC v2.0 and Common Terminology Criteria for Adverse Events v3.0 (CTCAE). Bethesda, MD: National Cancer Institute, 2006. Available at http://ctep.info.nih.gov/reporting/ctc.html
23. Nannini M, Astolfi A, Paterini P, Urbini M, Santini D, Catena F, Indio V, Casadio R, Pinna AD, Biasco G, Pantaleo MA (2013) Expression of IGF-1 receptor in KIT/PDGF receptor-α wild-type gastrointestinal stromal tumors with succinate dehydrogenase complex dysfunction. Future Oncol 9(1):121-126. doi:10.2217/fon.12.170
24. Pappo AS, Patel SR, Crowley J et al (2011) R1507, a monoclonal antibody to the insulin-like growth factor 1 receptor, in patients with recurrent or refractory Ewing sarcoma family of tumors: results of a phase II sarcoma alliance for research through collaboration study. J Clin Oncol 29:4541-4547
25. Jassem J, Langer CJ, Karp DD et al (2010) Randomized, open label, phase III trial of figitumumab in combination with paclitaxel and carboplatin versus paclitaxel and carboplatin in patients with non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol; 28 (suppl): abstr 7500
26. Robertson JFR, Ferrero J-M, Bourgeois H et al (2013) Ganitumab with either exemestane or fulvestrant for postmenopausal women with advanced, hormone-receptor-positive breast cancer: a randomised, controlled, double-blind, phase 2 trial. Lancet Oncol; published online Feb 13
27. Di Cosimo S, Scaltriti M, Val D et al (2007) The PI3-K/AKT/mTOR pathway as a target for breast cancer therapy. Proc Am Soc Clin Oncol. Abstr 3511